Loading
The European oncology society's 2021 guideline for breast cancer that has spread, the parent document of the living guideline that is now updated as trials read out.
ESMO Clinical Practice Guideline for metastatic breast cancer, published in Annals of Oncology in 2021 by Gennari, André, Barrios, Cortés and colleagues. Europe PMC indexes no abstract for this article, so OnCo carries no figures from it. For triple-negative disease it set pembrolizumab with chemotherapy for PD-L1 combined positive score of 10 or more (KEYNOTE-355), PARP inhibitors for germline BRCA carriers (OlympiAD, EMBRACA) and sacituzumab govitecan after two lines (ASCENT). The guideline has since been maintained as the ESMO Metastatic Breast Cancer Living Guideline, whose 2025 update is recorded separately.
The document that made immunotherapy, PARP inhibition and the first antibody-drug conjugate the European standard for metastatic triple-negative disease; every later first-line change is an amendment to it.
Shares ESMO Clinical Practice Guidelines & MCBS, European Society for Medical Oncology (ESMO), Annals of Oncology, HER2-positive breast cancer and the tag tnbc-evidence.
Shares Annals of Oncology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares EMBRACA, OlympiAD, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Annals of Oncology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Javier Cortés, Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Javier Cortés, Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.